Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

We came across a bullish thesis on Vericel Corporation on R.Dennis’s Substack by OppCost. In this article, we will summarize ...

Bioventus Inc. (NASDAQ:BVS) is one of the best undervalued medical device stocks to buy now. On July 7, Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus Inc. (NASDAQ:BVS) with an ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection ...

Tempus AI dropped for a second day on Monday, shedding 4.48 percent to close at $63.54 apiece following the announcement of a $400-million debt issuance.

The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinical workflows, enabling earlier disease detection and opening ...

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines.

TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM ...

An AI health care stock backed by Nancy Pelosi and Cathie Wood is drawing criticism from Jim Cramer.